We are live on ! Find out more
SLN

Silence Therapeutics
SLN

56 hedge funds and large institutions have $102M invested in Silence Therapeutics in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 11

3.85% more ownership

Funds ownership: 38.3% → 42.15% (+3.9%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

4% less capital invested

Capital invested by funds: $106M → $102M (-$3.99M)

3% less funds holding

Funds holding: 58 → 56 (-2)

48% less call options, than puts

Call options by funds: $100K | Put options by funds: $192K

Holders
56
Holders Change
-2
Holders Change %
-3.45%
% of All Funds
0.69%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
6
Increased
24
Reduced
11
Closed
6
Calls
$100K
Puts
$192K
Net Calls
-$92K
Net Calls Change
+$185K

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$5.45M
2
NCM
Nantahala Capital Management
Connecticut
+$3.33M
3
Millennium Management
Millennium Management
New York
+$2.28M
4
TAM
TFG Asset Management
Cayman Islands
+$1.46M
5
GPP
Great Point Partners
Connecticut
+$1.17M

Top Sellers

1
VC
Vivo Capital
California
-$6.72M
2
Morgan Stanley
Morgan Stanley
New York
-$1.43M
3
LOAMU
Lombard Odier Asset Management (USA)
New York
-$1.15M
4
II
Ishara Investments
California
-$548K
5
OM
Opaleye Management
Massachusetts
-$480K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
1
TCG Crossover Management
California
$16M – – –
SL
2
Siren LLC
Connecticut
$15.3M – – –
RG
3
Redmile Group
California
$11.4M – – –
NCM
4
Nantahala Capital Management
Connecticut
$11.3M +$3.33M +604,304 +39%
Citadel Advisors
5
Citadel Advisors
Florida
$6.51M +$5.45M +990,746 +406%
Millennium Management
6
Millennium Management
New York
$5.66M +$2.28M +414,599 +63%
GPP
7
Great Point Partners
Connecticut
$5.38M +$1.17M +212,457 +26%
NI
8
Nextech Invest
Switzerland
$5.02M – – –
TAM
9
TFG Asset Management
Cayman Islands
$3.32M +$1.46M +264,792 +72%
5VM
10
5AM Venture Management
California
$2.51M – – –
IC
11
Ikarian Capital
Texas
$1.73M – – –
JHC
12
Jones Hill Capital
New York
$1.59M +$1.66M +301,604 New
SG Americas Securities
13
SG Americas Securities
New York
$1.51M +$167K +30,358 +12%
UBS Group
14
UBS Group
Switzerland
$1.3M +$217K +39,424 +19%
BFM
15
Boothbay Fund Management
New York
$1.1M – – –
BlackRock
16
BlackRock
New York
$1.08M +$725K +131,624 +180%
Bank of Montreal
17
Bank of Montreal
Ontario, Canada
$1.07M +$234K +42,427 +26%
ACM
18
ADAR1 Capital Management
Texas
$907K +$818K +148,514 +628%
Marshall Wace
19
Marshall Wace
United Kingdom
$894K +$76.7K +13,936 +9%
SFCM
20
Seven Fleet Capital Management
California
$826K +$50.4K +9,159 +6%
BNP Paribas Financial Markets
21
BNP Paribas Financial Markets
France
$778K +$747K +135,641 +1,128%
II
22
Ishara Investments
California
$740K -$548K -99,500 -41%
HSBC Holdings
23
HSBC Holdings
United Kingdom
$640K -$275K -50,000 -29%
Point72 Asset Management
24
Point72 Asset Management
Connecticut
$631K +$31.1K +5,641 +5%
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
$608K +$542K +98,415 +584%
1
2 3

SLN Hedge Fund Activity: Q1 2026 in Review

56 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q1 2026, worth a combined $102M — down 3.8% from $106M a quarter earlier.

Fund positioning in SLN was balanced in Q1 2026: 6 funds opened new positions, 6 closed out, 24 added to existing stakes and 11 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $5.45M. The largest seller was Vivo Capital, exiting entirely with an estimated $6.72M sold.

  • 56 institutional investors held Silence Therapeutics (SLN) as of Q1 2026, down from 58 in Q4 2025.
  • Funds reported $102M of Silence Therapeutics stock for Q1 2026, down 3.8% quarter-over-quarter.
  • 6 funds opened new Silence Therapeutics positions in Q1 2026 and 6 closed out, a net change of 0 holders.
  • The largest Silence Therapeutics buyer in Q1 2026 was Citadel Advisors, an estimated $5.45M added.
  • The largest Silence Therapeutics seller in Q1 2026 was Vivo Capital, an estimated $6.72M sold.

Based on aggregated 13F filings for Q1 2026.